Tesamorelin

Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor to prompt the pituitary to release the body's own growth hormone. It is supplied here as an analytical-grade reference material for laboratory research use only.

Tesamorelin works one step upstream. Instead of supplying growth hormone directly, it stimulates the GHRH receptor so the pituitary makes its own — which tends to preserve the body's natural pulsing rhythm of release.

Its most-studied effect in clinical trials is reducing visceral adipose tissue — deep abdominal fat — in people with HIV-associated fat redistribution (lipodystrophy). Later studies also examined its effect on liver fat and on IGF-1 and other metabolic markers.

Yes, more than most compounds in this group — it has been through human trials and reached regulatory approval as a GHRH analog. The main caveat is scope: that evidence is concentrated in HIV-associated lipodystrophy and specific metabolic readouts, not broad benefits in the general population.

No. It is sold strictly as a reference material for laboratory research use only — not for human or veterinary use, and not as a drug or supplement.